A large retrospective review of patients with melanomas reported that BRAF and NRAS mutations were more likely to have CNS involvement at the time of diagnosis, and NRAS mutant melanomas were an independent predictor of shorter survival times in metastatic melanomas compared to BRAF mutant and wild-types [83]. The gene discussed is NRAS; the disease is melanoma.